§ 864.7040  Adenosine triphosphate release assay.
  (a) Identification. An adenosine triphosphate release assay is a device that measures the release of adenosine triphosphate (ATP) from platelets following aggregation. This measurement is made on platelet-rich plasma using a photometer and a luminescent firefly extract. Simultaneous measurements of platelet aggregation and ATP release are used to evaluate platelet function disorders.
  (b) Classification. Class I (general controls).

§ 864.9 Antithrombin III assay.
  (a) Identification. An antithrombin III assay is a device that measures the concentration of antithrombin III (a substance which acts with the anticoagulant heparin to prevent coagulation). This determination is used to monitor the administration of heparin in the treatment of thrombosis. The determination may also be used in the diagnosis of thrombophilia (a congenital deficiency of antithrombin III).
  (b) Classification. Class II (performance standards).

§ 864.10 Red blood cell enzyme assay.
  (a) Identification. Red blood cell enzyme assay is a device used to measure the activity in red blood cells of clinically important enzymatic reactions and their products, such as pyruvate kinase or 2,3-diphosphoglycerate. A red blood cell enzyme assay is used to determine the enzyme defects responsible for a patient’s hereditary hemolytic anemia.
  (b) Classification. Class II (performance standards).

§ 864.14 Activated whole blood clotting time tests.
  (a) Identification. An activated whole blood clotting time test is a device, used to monitor heparin therapy for the treatment of venous thrombosis or pulmonary embolism by measuring the coagulation time of whole blood.
  (b) Classification. Class II (performance standards).

§ 864.25 Erythropoietin assay.
  (a) Identification. An erythropoietin assay is a device that measures the concentration of erythropoietin (an enzyme that regulates the production of red blood cells) in serum or urine. This assay provides diagnostic information for the evaluation of erythrocytosis (increased total red cell mass) and anemia.
  (b) Classification. Class II. The special control for this device is FDA’s “Document for Special Controls for Erythropoietin Assay Premarket Notification (510(k)s).”

§ 864.275 Euglobulin lysis time tests.
  (a) Identification. A euglobulin lysis time test is a device that measures the length of time required for the lysis (dissolution) of a clot formed from fibrinogen in the euglobulin fraction (that fraction of the plasma responsible for the formation of plasmin, a clot lysing enzyme). This test evaluates natural fibrinolysis (destruction of a blood clot after bleeding has been arrested). The test also will detect accelerated fibrinolysis.
  (b) Classification. Class II (performance standards).